Zobrazeno 1 - 10
of 242
pro vyhledávání: '"Akira Sawaki"'
Autor:
Hiroshi Matsuoka, Takahiro Hayashi, Karen Takigami, Kazuyoshi Imaizumi, Ryoichi Shiroki, Naoki Ohmiya, Kazumitsu Sugiura, Kenji Kawada, Akira Sawaki, Koutaro Maeda, Yousuke Ando, Ichiro Uyama
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-8 (2020)
Abstract Background Immune checkpoint inhibitors (ICIs) targeting programmed cell death protein 1 (PD-1) are used for the treatment of various cancer types. However, immune-related adverse events (irAEs) occur in patients treated with ICIs. Several s
Externí odkaz:
https://doaj.org/article/f2146f7cbe92496ba12c5d39c12cdd8b
Publikováno v:
Internal Medicine; 2023, Vol. 62 Issue 24, p3625-3630, 6p
Autor:
Kazunori Nakaoka, Senju Hashimoto, Naoto Kawabe, Teiji Kuzuya, Seiji Yamada, Akira Sawaki, Kohei Funasaka, Mitsuo Nagasaka, Yoshihito Nakagawa, Ryoji Miyahara, Tomoyuki Shibata, Tetsuya Tsukamoto, Yoshiki Hirooka
Publikováno v:
Clinical Journal of Gastroenterology. 15:256-262
Autor:
Keitaro Matsuo, Hideo Tanaka, Yasushi Yatabe, Kazuo Tajima, Miki Watanabe, Takakazu Kawase, Satoyo Hosono, Hidemi Ito, Takashi Ura, Takashi Shibata, Daisuke Takahari, Tomoya Yokota, Hiroki Kawai, Masahiro Tajika, Akira Sawaki, Seiji Ito, Kei Muro, Kohei Shitara
Background: A relationship between dietary folate intake and efficacy of fluorouracil (FU) is supported by preclinical data. Furthermore, there are several reports that evaluated genetic polymorphisms of MTHFR (methylenetetrahydrofolate reductase) or
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::186094323fec93d5bf7949bf61caf3a3
https://doi.org/10.1158/1055-9965.c.6515139
https://doi.org/10.1158/1055-9965.c.6515139
Autor:
Keitaro Matsuo, Hideo Tanaka, Yasushi Yatabe, Kazuo Tajima, Miki Watanabe, Takakazu Kawase, Satoyo Hosono, Hidemi Ito, Takashi Ura, Takashi Shibata, Daisuke Takahari, Tomoya Yokota, Hiroki Kawai, Masahiro Tajika, Akira Sawaki, Seiji Ito, Kei Muro, Kohei Shitara
Supplementary Tables 1-3 from Folate Intake along with Genetic Polymorphisms in Methylenetetrahydrofolate Reductase and Thymidylate Synthase in Patients with Advanced Gastric Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3040f610d58ec527dd967ea5a0977d2e
https://doi.org/10.1158/1055-9965.22435875
https://doi.org/10.1158/1055-9965.22435875
Autor:
Kazunori, Nakaoka, Senju, Hashimoto, Naoto, Kawabe, Teiji, Kuzuya, Seiji, Yamada, Akira, Sawaki, Kohei, Funasaka, Mitsuo, Nagasaka, Yoshihito, Nakagawa, Ryoji, Miyahara, Tomoyuki, Shibata, Tetsuya, Tsukamoto, Yoshiki, Hirooka
Publikováno v:
Clinical journal of gastroenterology. 15(1)
Pancreatic neuroendocrine neoplasms (PNENs) are relatively rare with a reported incidence of 1-2/100,000 and generally thought to originate from the precursor of the neuroendocrine cells including the islet and the pancreatic duct cells. About 65% of
Autor:
Akira Sawaki, Teiji Kuzuya, Ryoji Miyahara, Atsushi Sugioka, Arisa Mii, Takuji Nakano, Yoshiki Hirooka, Naoto Kawabe, Kazunori Nakaoka, Yohei Miyachi, Hiroyuki Tanaka, Sayaka Kamejima, Takeshi Takahara, Yutaro Kato, Senju Hashimoto
Publikováno v:
Oncology. 100(1)
Introduction: The aim of this study was to investigate the early changes in alpha-fetoprotein (AFP) and des-γ-carboxy prothrombin (DCP) levels in patients with advanced hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab and to
Autor:
Yukinori Kurokawa, Toshirou Nishida, Akira Sawaki, Yoshito Komatsu, Tsuyoshi Takahashi, Masato Ozaka, Yoichi Naito, Toshihiko Doi, Shuichi Ohkubo
Publikováno v:
European Journal of Cancer. 121:29-39
Aim We evaluated the efficacy and safety of TAS-116, a novel class of an orally active selective inhibitor of heat shock protein 90, in patients with advanced gastrointestinal stromal tumour (GIST) after failure of three or more lines of standard tre
Autor:
Akira Sawaki, Tetsuhide Ito, Satoshi Hashigaki, Kazuo Sato, Masayuki Tori, Nobuyuki Kimura, Emiko Ohki, Takuji Okusaka
Publikováno v:
Japanese Journal of Clinical Oncology
This open-label Phase II trial supports the efficacy and safety of sunitinib in Japanese patients with panNETs. Dose reductions and interruptions are critical to maximize the efficacy of sunitinib.
Background In an interim analysis of a Phase II
Background In an interim analysis of a Phase II
Autor:
Akira Sawaki, Yukinori Kurokawa, Yoshitaka Honma, Yoichi Naito, Shiro Iwagami, Hideo Baba, Yoshito Komatsu, Toshirou Nishida, Toshihiko Doi
Publikováno v:
Annals of Oncology. 33:S467